Drugs / ODM-207
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03035591 | Dec 2016 → May 2019 | cancer | Orion Corporation, Orion Pharma | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ODM-207 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03035591 ↗ |
| Known as | Bet-in-4 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095190 ↗ |
| Action | Inhibit | “the BET inhibitor ODM-207” PMID 32989226 ↗ Sep 2020 |
| Modality | Small molecule | — CHEMBL5095190 ↗ |
| Route | Oral | “ODM-207 was administered orally once daily.” PMID 32989226 ↗ Sep 2020 |